trending Market Intelligence /marketintelligence/en/news-insights/trending/2qiDH563ZHDCn7dJxBSKNg2 content esgSubNav
In This List

Minerva Neurosciences appoints chief medical officer

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Minerva Neurosciences appoints chief medical officer

Minerva Neurosciences Inc. appointed Michael Davidson chief medical officer, to lead strategic development and clinical advancement of the company's products for schizophrenia, insomnia, major depressive disorder and Parkinson's disease.

Davidson is professor of psychiatry at the Sackler School of Medicine, Tel Aviv University, and has worked as a consultant for Pfizer Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Roche Holding Ltd., Novartis AG, Eli Lilly & Co., BioLineRx Ltd. and Takeda Pharmaceutical Co. Ltd., among others.